REGEN-COV prevents symptomatic COVID-19 infections, finds analysis

REGEN-COV prevents symptomatic COVID-19 infections, finds analysis Interim data from the Phase III trial evaluating REGEN-COV™ as a passive vaccine to prevent COVID-19 finds it reduces overall infection rate, viral load and length of infection. European Pharmaceutical Review

See also:

• Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization (open access preprint) bioRxiv
• Regen-cov™ antibody cocktail is active against sars-cov-2 variants first identified in the UK and South Africa REGENRON
• New Covid antibody drug found to prevent 100% of symptomatic infections in NHS trials Northampton Chronicle and Echo
• COVID-19: Breakthrough treatment claims to stop 100% of symptomatic infections Sky News